TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response.
SJ Isakoff, Leif W. Ellisen(Harvard University), M. C. Liu, C. A. Quadrino, LA Carey, Patrick J. Ryan(Texas A&M University), J. E. Garber(Beth Israel Deaconess Medical Center), Vered Stearns(Johns Hopkins University), Dianne M. Finkelstein(Harvard University), Karen J. Krag, Eric P. Winer(University of Vermont), Erica L. Mayer(Harvard University), Darrell R. Borger(Massachusetts Eye and Ear Infirmary), H. S. Rugo, Tiffany A. Traina(Memorial Sloan Kettering Cancer Center), SE Come, Paul E. Goss(Harvard University)
Cited by 35
Related Papers
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k